Similar articles

• Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries.

  Spectar JM. Spectar JM. Houst J Int Law. 2002;24(2):227-78. Houst J Int Law. 2002. PMID: 16189914 No abstract available.
• USA pressured to ease trade demands.

  Ahmad K. Ahmad K. Lancet. 2004 Mar 6;363(9411):790. doi: 10.1016/S0140-6736(04)15723-1. Lancet. 2004. PMID: 15022641 No abstract available.
• International intellectual property strategies for therapeutic antibodies.

  Storz U. Storz U. MAbs. 2011 Nov-Dec;3(6):596-606. doi: 10.4161/mabs.3.6.17788. Epub 2011 Nov 1. MAbs. 2011. PMID: 22123063 Free PMC article.
• A consideration of the patentability of enantiomers in the pharmaceutical industry in the United States.

  Miller CP, Ullrich JW. Miller CP, et al. Chirality. 2008 Jun;20(6):762-70. doi: 10.1002/chir.20520. Chirality. 2008. PMID: 18200591 Review.
• The North American Free Trade Agreement's effect on pharmaceutical patents: a bitter pill to swallow or a therapeutic solution?

  Silbermann JM. Silbermann JM. J Contemp Health Law Policy. 1996 Spring;12(2):607-36. J Contemp Health Law Policy. 1996. PMID: 8666736 Review. No abstract available.